Sydney, Australia 4 April 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”) announced on Tuesday, 26 March 2024, a fully underwritten pro rata accelerated non-renounceable entitlement offer (“Entitlement Offer”) to eligible shareholders to subscribe for one (1) new fully paid ordinary Clarity share (“New Share”) for every thirty three (33) existing fully paid ordinary Clarity…
Sydney, Australia 28 March 2024 Highlights Clarity has successfully completed the Placement and Institutional Entitlement Offer component of its capital raising, raising $110 million in total The Placement and Institutional Entitlement Offer received strong support from a broad range of new and existing institutional investors The strengthened balance sheet provides Clarity with funding to continue…
Sydney, Australia 26 March 2024 Highlights Launch of fully underwritten equity raising of $121 million (before costs) The offer will comprise an institutional placement to raise approximately $101 million, and a 1 for 33 pro-rata accelerated non-renounceable entitlement offer to eligible Clarity shareholders to raise approximately $20 million Post completion of the Offer Clarity will…
Sydney, Australia 22 March 2024 Highlights First participant in cohort 4 (first multi-dose cohort) in the theranostic SECuRE trial has been treated with 67Cu-SAR-bisPSMA at 12GBq. The SECuRE trial is investigating 64Cu/67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) patients. Fifteen patients have been treated so far at 3 different dose levels of 67Cu-SAR-bisPSMA (single cycle):…
Sydney, Australia 15 March 2024 Highlights Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been completed in 6 participants who received therapy with 67Cu-SAR-bisPSMA at the highest single dose level of 12GBq. No dose limiting toxicities (DLTs) have been reported in cohort 3 to date. An overall…
Sydney, Australia 6 March 2024 Highlights Clarity recently reported that in its diagnostic Phase 1/2 trial, COBRA, 64Cu-SAR-bisPSMA was found to be safe and highly effective in detecting prostate cancer (PC) lesions in patients with biochemical recurrence (BCR). In trial participants where standard of care (SOC) imaging was unable to detect any lesions, up to…
Sydney, Australia 15 February 2024 Highlights Initial data from Clarity’s diagnostic Phase 1/2 trial, COBRA, confirms 64Cu-SAR-bisPSMA is safe and highly effective in detecting prostate cancer (PC) lesions in patients with biochemical recurrence (BCR). Confirmed unique benefit of 64Cu-SAR-bisPSMA for next-day imaging in this patient population, with more lesions and more patients with a positive…
Sydney, Australia 16 January 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, advises that Clarity’s Non-Executive Director, Ms Cheryl Maley, is resigning effective immediately to focus on her new full-time role as Chief…
Sydney, Australia 23 December 2023 Highlights First patient safely dosed in the pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial. The aim of the CLARIFY trial is to detect regional nodal metastases in participants with prostate cancer prior to radical prostatectomy. Final results from the CLARIFY trial are intended to provide sufficient evidence to support an application…
Sydney, Australia 19 December 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the early recruitment closure for its Phase II diagnostic 64Cu-SARTATE trial, DISCO (NCT04438304)1, for patients with known or…